Last reviewed · How we verify
TFX06 tablet
At a glance
| Generic name | TFX06 tablet |
|---|---|
| Sponsor | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of TFX06 in Women With Advanced Breast Cancer. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TFX06 tablet CI brief — competitive landscape report
- TFX06 tablet updates RSS · CI watch RSS
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd. portfolio CI